Skip to content
TrialScanner

NCT03790709

ANAVEX2-73 for Treatment of Early Alzheimer's Disease

Phase 2/Phase 3CompletedAVXLLead

Registry record

Lead sponsor
Anavex Life Sciences Corp.
Conditions
Alzheimer Disease
Primary completion
Jun 30, 2022Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03790709 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03790709: ANAVEX2-73 for Treatment of... | TrialScanner